Opens in a new tab

(pre-)Clinical research to understand alopecia and improve cooling results

Netherlands Comprehensive Cancer Organisation, 2015.
Type:
Poster
Link:
PMID:
DOI:
Authors:

C. van den Hurk1, M. Komen2, O. Hussain3, 4, W. Al-Tameemi3, R. Paus5, 6, A. Collett3, I. Haslam5, A. Young7, H. Mc Vicars8, J. Ross9, N. T. Georgopoulos3

Access Paper

1Netherlands Comprehensive Cancer Organisation, IKNL (NL)
2Medical Centre Alkmaar (NL)
3Huddersfield University (GB)
4Paxman Coolers Ltd (GB)
5Manchester University (GB),
6Münster University (DE)
7Warwick University (GB)
8Western General Hospital (GB)
9Royal Marsden Hospital (GB)

Related papers:

Abstract P5-08-10: Safety and Tolerability of Paxman Scalp Cooling at Lower Temperatures to Improve Efficacy with Anthracycline Chemotherapy

View

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

View

Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial

View

Abstract

Purpose

• Authors: international multi-disciplinary special interest group (SIG) on chemotherapy-induced alopecia (CIA) & scalp cooling
• Pathobiology of CIA is still not fully understood1
• Prevention of CIA by scalp cooling (Fig 1):
– Well tolerated by patients
– Overall 50% satisfactory results
– Increasingly used world wide
• Goal of SIG: study CIA by combining pre-clinical & clinical research, ultimately improving efficacy of scalp cooling

Methods

Study mechanism of CIA & preventative role of cooling:
A. Studying in vitro cell toxicity models, using a variety of cultured keratinocytes (including human hair follicular keratinocytes, normal epidermal human keratinocytes & immortalised human keratinocytes)

B. Clinical investigation into the role of post-infusion scalp cooling times (PICT) & scalp skin temperature on severity of CIA

C. Investigate intracellular pathways mediating damage to human hair follicle-associated cell populations

Results

A. Cooling rescues cells in culture from cytotoxicity caused by doxorubicin, docetaxel & the active metabolite of cyclophosphamide (4-OH-cyclophosphamide) (Fig 2 & 3).2 Observations are extended to series of other commonly used chemotherapy drugs, e.g. paclitaxel

B. No significant differences in CIA found for PICTs of 90, 45 & 20 minutes in 3-weekly docetaxel chemotherapy (75 or 100 mg/m2).3 Degree of CIA is temperature dependent, best results for anthracyclines obtained at temperatures <20ºC4

C. A feasible method to determine P53 in hair follicle-associated cell populations has been developed

Conclusion

• Cooling reduces cell death when exposed to a range of chemotherapeutic drugs, reflecting clinical outcomes
• Dose is a determining factor, but half-life times of cytotoxics do not seem to be the most important factor for the optimal PICT
• Adapting scalp cooling temperatures to individual scalp skin temperatures could enhance results
• Combining pre-clinical & clinical research supports development of a patient tailored approach with the ultimate goal to prevent CIA for our patients & thereby improve their quality of life

Related papers

“Dear hair loss” – illness perceptions of female patients with chemotherapy-induced alopecia

Chemotherapy-induced alopecia (CIA) is one of the most common and distressing side effects of chemotherapy treatment. This study aims to assess the illness perceptions of…

View

A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention

Chemotherapy-induced alopecia (CIA) is the most visibly distressing side effect of commonly administered chemotherapeutic agents. Because psychological health has huge relevance to lifestyle, diet, and…

View

A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy

Alopecia is a distressing and common side-effect of chemotherapy, especially anthracycline- and taxane-containing regimen. A series of studies and reviews have considered scalp cooling as…

View
Get the Paxman System

Wherever you are in the world, it’s easy to give patients access to our chemotherapy side effect management solutions and a degree of control. Fill out the form to get started.

Get Paxman in your country with our global locator